|
Syncona Ltd - London-based investment company - Invests more into OMass Therapeutics, an Oxford University biotechnology spin-out. After the new £15 million investment, Syncona now holds a 31% stake worth £44 million in the developer of small molecule drugs. The £15 million is part of an oversubscribed £75.5 million second round of funding for OMass, which now has raised £119 million in total.
‘We are pleased with this financing round which will support OMass as it looks to progress its pipeline of small molecule drugs,’ comments OMass Chair Edward Hodgkin in a press release. OMass produces drugs that treat rare diseases and immunological conditions.
Current Syncona stock price: 170.20 pence, up 1.7% on Thursday
12-month change: down 25%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
